KDR and small cell lung carcinoma: In this review, we will summarize the main results obtained by targeting angiogenesis pathway with a monoclonal antibody anti VEGF (bevacizumab) or with small-molecule tyrosine kinase inhibitors of VEGFR in SCLC.